CHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On February28, 2017, the Compensation Committee (the Committee)
of the Board of Directors of ChemoCentryx, Inc. (the Company)
approved a 3.5percent increase to the base salaries to be paid to
the named executive officers listed below (the NEOs), effective
January1, 2017. On February28, 2017, the Committee also approved
cash bonuses to be paid to the NEOs listed below for the 2016
fiscal year and approved and awarded the stock options and
restricted stock units listed below to the NEOs under the
Companys 2012 Equity Incentive Award Plan. The exercise price per
share of such stock options is $6.62, the closing price per share
of the Companys common stock on the NASDAQ Global Select Market
on February28, 2017. Twenty-five percent of the total number of
shares of common stock subject to each NEOs option will vest on
January1, 2018, and 1/48th of the total number of shares of
common stock subject to such option will vest monthly thereafter,
subject to such NEOs continued employment or service relationship
with the Company on each such vesting date. One third of each of
the NEOs restricted stock unit awards will vest on January1,
2018, and the remaining two thirds of each of the NEOs restricted
stock unit awards will vest on January1, 2019 and January1, 2020,
respectively, subject to such NEOs continued employment or
service relationship with the Company on each such vesting date.
The 2016 actual cash bonus payments, stock option grants and
restricted stock unit awards are as follows:
| Name | Title |
2016Actual CashBonus |
Stock Options |
RestrictedStockUnit Awards |
||||||||||
|
Thomas J. Schall, Ph.D. |
President and Chief Executive Officer |
$ | 285,725 | 280,000 | 100,000 | |||||||||
|
Susan M. Kanaya |
Executive Vice President, Chief Financial and |
$ | 176,214 | 110,000 | 40,000 | |||||||||
|
Petrus Bekker, M.D., Ph.D. |
Chief Medical Officer |
$ | 143,642 |
About CHEMOCENTRYX, INC. (NASDAQ:CCXI)
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases. CHEMOCENTRYX, INC. (NASDAQ:CCXI) Recent Trading Information
CHEMOCENTRYX, INC. (NASDAQ:CCXI) closed its last trading session up +0.17 at 6.99 with 83,510 shares trading hands.